Welcome to our dedicated page for Verve Therapeutics SEC filings (Ticker: VERV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Verve Therapeutics filings document the formal wind-down of its public-company registration following the completed acquisition by Eli Lilly and Company. The record includes acquisition-related Form 8-K material-event reports, common-stock listing information for the Nasdaq Global Select Market, a Form 25 notification removing the common stock from exchange listing and Section 12(b) registration, and a Form 15 terminating or suspending Exchange Act reporting duties for the common stock.
Earlier disclosure categories included material agreements, shareholder voting matters, governance matters, capital-structure disclosure, operating and financial results, risk factors, and clinical or regulatory information related to Verve's genetic-medicine programs for cardiovascular disease.
Pentwater Capital Management LP and Matthew Halbower disclosed ownership of 6,720,000 shares of Verve Therapeutics common stock, representing 7.5% of the outstanding class. The filing states this percentage is calculated using 89,143,237 shares outstanding as of May 7, 2025. The shares are directly held by the Pentwater Funds, with Pentwater acting as investment manager and Mr. Halbower identified as the individual connected to the investment manager. The Reporting Persons assert the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
Verve Therapeutics (VERV): This Schedule 13G/A amendment reports that the listed Reporting Persons — including Biotechnology Value Fund, L.P., related BVF entities and Mark N. Lampert — no longer beneficially owned any shares of Verve Therapeutics as of the close of business on June 30, 2025. The filing identifies the class as Common Stock (CUSIP 92539P101) and provides reporting persons' addresses and citizenships. All cover-page ownership fields show 0 shares (0%). The amendment is signed by Mark N. Lampert with signature dates of August 14, 2025.